Roche diabetes app replaces blood glucose meter
Diabetes patients can use an app developed by Roche to determine their blood sugar levels on the basis of two photos taken on a cell phone camera. The Basel-based pharma group has now received the CE Mark for its app, paving the way for it to be marketed throughout Europe and in other countries around the world.
Roche in Basel (img: Roche)
Roche has removed the need for diabetes patients to use blood sugar measuring devices. The Accu-Chek Sugar View app developed by the Basel-based pharmaceutical company allows blood sugar levels to be tested using special test strips and two photos taken with a cell phone camera, as outlined in a press release. Roche has now received the CE Mark for its app, which confirms that the product complies with the applicable requirements. The CE Mark is a prerequisite for successful marketing across Europe and in other countries.
Roche will now make the app widely available for certain smartphone models via the Google Play Store. “The broad launch of this state-of-the art digital solution can offer a huge benefit to people in-between doctors’ visits and to those not having access to appropriate diabetes care and blood glucose monitoring”, explained Marcel Gmünder, Global Head of Roche Diabetes Care, in the press release. An additional advantage is that the app represents an affordable solution for those suffering from diabetes, Gmünder commented further.
Users take an Accu-Chek Active test strip and then take two photos on their smartphone camera. The app leads the user through an easy-to-follow process until a dedicated algorithm assigns the blood glucose result on the test strip to one of the categories ranging from “low” to “very high”. Based on this assessment, the user receives suggested actions including, for example, a prompt to eat something.
Share this article
You might also be interested in
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.Read More
The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.Read More
The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.Read More
Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.Read More
Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.Read More
We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.Read More